1. Serum zonulin and colorectal cancer risk.
- Author
-
Marino M, Mignozzi S, Michels KB, Cintolo M, Penagini R, Gargari G, Ciafardini C, Ferraroni M, Patel L, Del Bo' C, Leone P, Airoldi A, Vecchi M, Bonzi R, Oreggia B, Carnevali P, Vangeli M, Mutignani M, Guglielmetti S, Riso P, La Vecchia C, and Rossi M
- Subjects
- Humans, Male, Middle Aged, Female, Aged, Case-Control Studies, Adult, Aged, 80 and over, Biomarkers, Tumor blood, Young Adult, Risk Factors, Cholera Toxin blood, Haptoglobins metabolism, Haptoglobins genetics, Protein Precursors blood, Colorectal Neoplasms blood, Colorectal Neoplasms microbiology, RNA, Ribosomal, 16S genetics
- Abstract
Intestinal permeability has been related to colorectal cancer (CRC) development. Zonulin, a protein able to regulate tight junction function and intestinal permeability, emerges as a promising marker to elucidate the contribution of bacterial translocation in CRC. An Italian case-control study included 77 CRC cases, 72 intestinal adenoma and 76 healthy controls (for a total of 148 tumor-free subjects), aged 20-85. Serum zonulin levels were quantified by ELISA kit and blood 16S rRNA gene copies by DNA extraction and polymerase chain reaction. We applied logistic regression models adjusted for center, sex, age and education. There was a positive association between zonulin and CRC risk. The odds ratio (OR) of CRC for the highest versus lowest tertile of zonulin as compared to tumor-free subjects was 2.36 (95% confidence interval, 1.14-4.86). The ORs were similar in colon and rectal cancers. The OR of colon cancer for the highest versus lowest levels of both zonulin and 16S rRNA gene copies was 4.55.Circulating levels of zonulin were higher in CRC patients compared to tumor-free controls supporting the hypothesis of an interplay of gut barrier dysfunction and bacterial translocation in colorectal carcinogenesis. Zonulin may interact with 16S rRNA gene copies and serve as a further biomarker in the evaluation of CRC diagnosis., Competing Interests: Declarations Ethics approval and consent to participate The study was conducted according to the guidelines of the Declaration of Helsinki, and ap-proved by the Ethics Committees of ASST Grande Ospedale Metropolitano Niguarda (No. 477–112016; November 25, 2016) and Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico (No. 742–2017; December 14, 2017). Written informed consent was obtained from all subjects involved in the study. Consent for publication All authors consent to the publication of the present version of the manuscript. Competing interests The authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF